<DOC>
	<DOCNO>NCT01220596</DOCNO>
	<brief_summary>Evaluate safety efficacy Peginterferon alfa-2a follow Entecavir compare Peginterferon alfa-2a monotherapy patient HBeAg positive chronic hepatitis B . - Increased HBeAg seroconversion rate - Increased HBsAg loss rate - To define best treatment condition chronic HBV hepatitis patient</brief_summary>
	<brief_title>Efficacy Study Sequential Therapy Peginterferon Alfa-2a Following Entecavir Patient With Chronic Hepatitis B .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Chronic hepatitis B patient HBeAg positive , HBsAg positive , HBV DNA &gt; 100,000 copies/ml antiHBs negative , serum ALT exceed 2 X ULN le 10 X ULN . Patient infect concurrently HCV , HDV HIV patient history antiviral treatment Hepatitis B patient hepatic decompensation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>